An open label tolerability and safety study of KRX-101 (sulodexide gelcaps) for the treatment of type 2 diabetic nephropathic patients with persistent microalbuminuria in Australia, New Zealand, and Hong Kong.

Trial Profile

An open label tolerability and safety study of KRX-101 (sulodexide gelcaps) for the treatment of type 2 diabetic nephropathic patients with persistent microalbuminuria in Australia, New Zealand, and Hong Kong.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Sulodexide (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Sponsors Keryx Biopharmaceuticals
  • Most Recent Events

    • 24 Mar 2008 Status changed from recruiting to terminated on clinicaltrials.gov.
    • 04 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top